I have posted the meeting minutes from the Immunogenicity Risk Assessment and Mitigation Group's August meeting. We would like to invite this community to a cross community discussion about challenges of impurities in the production of your therapeutic modalities and immunogenicity assessments.
Thank you
Robin Walsh
------------------------------
Robin Walsh MS, SSCYM (ASCP)CM
Consultant Toxicologist
Eli Lilly and Company
Indianapolis IN
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------